219 related articles for article (PubMed ID: 30215656)
1. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
3. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
4. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.
Joniau S; Briganti A; Gontero P; Gandaglia G; Tosco L; Fieuws S; Tombal B; Marchioro G; Walz J; Kneitz B; Bader P; Frohneberg D; Tizzani A; Graefen M; van Cangh P; Karnes RJ; Montorsi F; Van Poppel H; Spahn M;
Eur Urol; 2015 Jan; 67(1):157-164. PubMed ID: 24486307
[TBL] [Abstract][Full Text] [Related]
5. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
8. A Metabolism-Related Gene Landscape Predicts Prostate Cancer Recurrence and Treatment Response.
Zhou L; Fan R; Luo Y; Zhang C; Jia D; Wang R; Zeng Y; Ren M; Du K; Pan W; Yang J; Tian F; Gu C
Front Immunol; 2022; 13():837991. PubMed ID: 35359973
[TBL] [Abstract][Full Text] [Related]
9. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients.
Avgeris M; Stravodimos K; Scorilas A
Biol Chem; 2014 Sep; 395(9):1095-104. PubMed ID: 25153390
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
11. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
12. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.
Briganti A; Wiegel T; Joniau S; Cozzarini C; Bianchi M; Sun M; Tombal B; Haustermans K; Budiharto T; Hinkelbein W; Di Muzio N; Karakiewicz PI; Montorsi F; Van Poppel H
Eur Urol; 2012 Sep; 62(3):472-87. PubMed ID: 22633803
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
15. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.
Stuchbery R; Macintyre G; Cmero M; Harewood LM; Peters JS; Costello AJ; Hovens CM; Corcoran NM
Oncotarget; 2016 May; 7(21):31384-92. PubMed ID: 27120785
[TBL] [Abstract][Full Text] [Related]
16. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
18. Docosahexaenoic acid differentially modulates the cell cycle and metabolism- related genes in tumor and pre-malignant prostate cells.
Tamarindo GH; Góes RM
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Oct; 1865(10):158766. PubMed ID: 32712248
[TBL] [Abstract][Full Text] [Related]
19. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
